Could a chemo boost after radiation tame aggressive prostate cancer?

NCT ID NCT06864533

Recruiting now Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing whether adding the chemotherapy drug docetaxel after standard treatment (radiation or surgery) can improve outcomes for men with a particularly aggressive form of prostate cancer (Gleason score 9-10). Participants will either receive standard treatment alone or standard treatment followed by several cycles of docetaxel. The study will track how long men live without their cancer returning or spreading, and whether the extra chemo improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: docetaxel (a chemotherapy drug), sometimes combined with carboplatin
What this could lead to: If effective, adding docetaxel after standard treatment could improve survival and delay cancer recurrence in men with high-risk prostate cancer.
What could go wrong: This is a non-randomized trial, so results may be less reliable. Chemotherapy can cause side effects, and it's uncertain if the benefits will outweigh risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY GLEASON SCORE PROSTATE CANCER RADIATION THERAPY

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.